Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $123.33

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $123.33.

Several research analysts recently weighed in on ZBH shares. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Raymond James decreased their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Royal Bank of Canada raised their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Wolfe Research started coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. Finally, Evercore ISI lowered their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $103.22 on Friday. The stock has a market cap of $20.55 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 1.96 and a beta of 1.02. Zimmer Biomet has a 12 month low of $101.47 and a 12 month high of $133.90. The company has a 50 day simple moving average of $108.36 and a two-hundred day simple moving average of $108.14. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.65 earnings per share. As a group, analysts predict that Zimmer Biomet will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Institutional Trading of Zimmer Biomet

Several large investors have recently added to or reduced their stakes in the stock. Dunhill Financial LLC raised its holdings in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank purchased a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $31,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at approximately $35,000. Finally, Quarry LP acquired a new position in Zimmer Biomet in the second quarter valued at approximately $53,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.